RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Hunan Cancer Hospital; 2 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  2. Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
  3. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06788002, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed with nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III)

    Inclusion criterion 2

  3. Stage IVB (AJCC 8th edition staging)

    Inclusion criterion 3

    Any cardiovascular risk factors, including: cardiac chest pain that restricts daily instrumental activities ≤28 days before treatment. Symptomatic pulmonary embolism within ≤3 months before treatment. Acute myocardial infarction within ≤6 months before treatment. History of heart failure meeting New York Heart Association (NYHA) Class III or IV within ≤6 months before treatment. Grade ≥2 ventricular arrhythmias within ≤6 months before treatment. History of cerebrovascular accident within ≤6 months before the first dose of the investigational drug.

    Exclusion criterion 15

  4. De novo nasopharyngeal carcinoma with liver metastasis, or patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion.

    Inclusion criterion 4

    Systemic anticancer therapy, including hormone therapy, administered within 28 days prior to the initiation of the study treatment.

    Exclusion criterion 3

    Previous treatment with immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4).

    Exclusion criterion 4

    Conditions requiring systemic corticosteroid therapy (equivalent to >10 mg/day of prednisone or similar medications) or other immunosuppressive therapy within ≤14 days prior to treatment.

    Exclusion criterion 7

    Any major surgery requiring general anesthesia within ≤28 days prior to treatment.

    Exclusion criterion 13

  5. ECOG performance status: 0 or 1

    Inclusion criterion 5

  6. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L; platelets ≥ 100 × 10\^9/L; hemoglobin ≥ 90 g/L.

    Inclusion criterion 7

    International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × upper limit of normal (ULN); activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN

    Inclusion criterion 8

    Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min.

    Inclusion criterion 9

  7. Must have at least one measurable lesion (assessed according to RECIST v1.1)

    Inclusion criterion 6

  8. Known history of HIV infection.

    Exclusion criterion 11

    Untreated chronic hepatitis B patients or hepatitis B virus (HBV) carriers with HBV DNA ≥500 IU/mL, or active hepatitis C virus (HCV) carriers.

    Exclusion criterion 12

  9. Age ≥ 18 years and ≤ 70 years, male or non-pregnant female.

    Inclusion criterion 1

    Pregnant or breastfeeding women.

    Exclusion criterion 21

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06788002, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years and ≤ 70 years, male or non-pregnant female.
  • Histologically confirmed with nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III)
  • Stage IVB (AJCC 8th edition staging)
  • De novo nasopharyngeal carcinoma with liver metastasis, or patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion.
  • ECOG performance status: 0 or 1
  • Must have at least one measurable lesion (assessed according to RECIST v1.1)
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L; platelets ≥ 100 × 10\^9/L; hemoglobin ≥ 90 g/L.
  • International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × upper limit of normal (ULN); activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
  • Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min.
  • Serum total bilirubin ≤ 1.5 × ULN (patients with Gilbert's syndrome may be included if total bilirubin < 3 × ULN); AST and ALT ≤ 5 × ULN (because of liver metastasis)

Exclusion Criteria:

  • Patients with tumor recurrence at the primary site who have previously received radical radiotherapy.
  • Tumor invasion involving major blood vessels, with a high risk of significant bleeding as assessed by the investigator.
  • Systemic anticancer therapy, including hormone therapy, administered within 28 days prior to the initiation of the study treatment.
  • Previous treatment with immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4).
  • Patients with active autoimmune diseases or a history of autoimmune diseases with a risk of recurrence.
  • Known history of other malignancies (except cured basal cell carcinoma or carcinoma in situ of the cervix).
  • Conditions requiring systemic corticosteroid therapy (equivalent to >10 mg/day of prednisone or similar medications) or other immunosuppressive therapy within ≤14 days prior to treatment.
  • Uncontrolled diabetes or laboratory abnormalities ≥Grade 1 in potassium, sodium, or corrected calcium levels despite standard treatment, or ≥Grade 3 hypoalbuminemia within ≤14 days before treatment.
  • History of the following diseases: interstitial lung disease, non-infectious pneumonitis, or uncontrolled diseases, including pulmonary fibrosis or acute lung disease.
  • Severe chronic or active infections requiring systemic antibiotics, antifungals, or antivirals within ≤14 days before the first dose of the investigational drug (including tuberculosis infection).
  • Known history of HIV infection.
  • Untreated chronic hepatitis B patients or hepatitis B virus (HBV) carriers with HBV DNA ≥500 IU/mL, or active hepatitis C virus (HCV) carriers.
  • Any major surgery requiring general anesthesia within ≤28 days prior to treatment.
  • Previous allogeneic stem cell transplantation or organ transplantation.
  • Any cardiovascular risk factors, including: cardiac chest pain that restricts daily instrumental activities ≤28 days before treatment. Symptomatic pulmonary embolism within ≤3 months before treatment. Acute myocardial infarction within ≤6 months before treatment. History of heart failure meeting New York Heart Association (NYHA) Class III or IV within ≤6 months before treatment. Grade ≥2 ventricular arrhythmias within ≤6 months before treatment. History of cerebrovascular accident within ≤6 months before the first dose of the investigational drug.
  • Evident bleeding tendencies or clinically significant bleeding symptoms ≤28 days prior to randomization, including but not limited to gastrointestinal bleeding, nasal bleeding (excluding epistaxis or retrograde blood-stained nasal discharge), and persistent bleeding disorders or coagulopathy.
  • Known allergy to any component of the investigational drug or a history of severe hypersensitivity to other monoclonal antibodies.
  • Peripheral neuropathy of Grade ≥2 as defined by NCI CTCAE v5.0.
  • Administration of live vaccines within ≤4 weeks prior to treatment.
  • Underlying medical conditions (including laboratory abnormalities) or alcohol/drug abuse or dependency that could impair drug administration, interpretation of drug toxicity, or adverse events (AEs), or could compromise study compliance or execution.
  • Pregnant or breastfeeding women.
  • Other factors deemed by the investigator that could lead to the premature termination of the study, such as other severe illnesses, significant laboratory abnormalities, or family/social factors that could affect participant safety or the collection of study data.

Quoted from ClinicalTrials.gov, NCT06788002, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06788002, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06788002